Adverse events in an integrated home-based treatment program for MDR-TB and HIV in kwazulu-natal, South Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 4, 2013, Pages 436-440

  Brust, James C M ^a   Shah, N Sarita ^a   Van Der Merwe, Theo L ^b   Bamber, Sheila ^b,c   Ning, Yuming ^a   Heo, Moonseong ^a   Moll, Anthony P ^b   Loveday, Marian ^d,e   Lalloo, Umesh G ^e   Friedland, Gerald H ^f   Gandhi, Neel R ^a,g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Philanjalo and Church of Scotland Hospital   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d Centre for the Study of the Social and Environmental   (South Africa)

^e UNIVERSITY OF KWAZULU NATAL   (South Africa)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g EMORY UNIVERSITY   (United States)

Author keywords

Adverse events; HIV; Multidrug resistant tuberculosis; Resource limited settings; Side effects

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CREATININE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LEVOTHYROXINE; OFLOXACIN; POTASSIUM; PYRAZINAMIDE; STAVUDINE; TENOFOVIR; THYROTROPIN; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG SAFETY; FEMALE; HEALTH PROGRAM; HEARING IMPAIRMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPOKALEMIA; HYPOTHYROIDISM; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; NAUSEA AND VOMITING; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; RURAL POPULATION; SEIZURE; SIDE EFFECT; SOUTH AFRICA; SUICIDAL IDEATION; TINNITUS; WEAKNESS;

EID: 85027920247     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31828175ed     Document Type: Article

References (21)

1. Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrugand extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80-86.
2. Seung KJ, Omatayo DB, Keshavjee S, et al. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One. 2009;4:e7186.
3. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348: 119-128.
4. Heller T, Lessells RJ, Wallrauch CG, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14:420-426.
5. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:648-655.
6. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11:1314-1320.
7. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrugresistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis. 2010;14:275-281.
8. Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:1373-1377.
9. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382-1384.
10. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrugresistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther. 2011;18:e29-e34.
11. Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:749-759.
12. Zager EM, McNerney R. Multidrug-resistant tuberculosis. BMC Infect Dis. 2008;8:10.
13. Brust JC, Shah NS, Scott M, et al. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis. 2012;16:998-1004.
14. Division of AIDS (DAIDS). Table for grading the severity of adult and pediatric adverse events. Available at: http://rcc.tech-res.com/ safetyandpharmacovigilance. Accessed August 1, 2011.
15. Lewis WC, Calden G, Thurston JR, et al. Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis. Dis Chest. 1957; 32:172-182.
16. Dutta BS, Hassan G, Waseem Q, et al. Ethionamide-induced hypothyroidism. Int J Tuberc Lung Dis. 2012;16:141.
17. Satti H, Mafukidze A, Jooste PL, et al. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. Int J Tuberc Lung Dis. 2012;16:468-472.
18. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India. PloS One. 2012;7:e40781.
19. Department of Health, South Africa. Multi-Drug Resistant Tuberculosis: A Policy Framework on Decentralized and Deinstitutionalized Management for South Africa. 2011 Available at: http://www.doh.gov.za/docs/policy/2011/policy-TB.pdf. Accessed December 26, 2012.
20. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-528.
21. Brust JC, Lygizos M, Chaiyachati K, et al. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS One. 2011;6:e15841.